Related Experiment Video
Updated: Jun 20, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Metastatic renal cell carcinoma with occult primary: a multicenter prospective cohort
Nicolas Jacquin1,2, Ronan Flippot3, Julien Masliah-Planchon4
1INSERM U830, Diversity and Plasticity of Childhood Tumors Lab, PSL Research University, Institut Curie Research Center, Paris, France.
Abstract:
Metastatic carcinoma of presumed renal origin (rCUP) has recently emerged as a new entity within the heterogeneous entity of Cancers of Unknown Primary (CUP) but their biological features and optimal therapeutic management remain unknown. We report the molecular characteristics and clinical outcome of a series of 25 rCUP prospectively identified within the French National Multidisciplinary Tumor Board for CUP. This cohort strongly suggests that rCUP share similarities with common RCC subtypes and benefit from renal-tailored systemic treatment. This study highlights the importance of integrating clinical and molecular data for optimal diagnosis and management of CUP.
Insights
Metastatic carcinoma of presumed renal origin (rCUP) is a newly identified cancer. This study suggests rCUP shares traits with common kidney cancers and benefits from targeted therapies.
Area of Science:
- Oncology
- Genitourinary Cancers
Background:
- Metastatic carcinoma of presumed renal origin (rCUP) is a recently recognized entity within cancers of unknown primary (CUP).
- The biological characteristics and optimal treatment strategies for rCUP are not well-defined.
- Understanding rCUP is crucial for improving patient outcomes in this challenging cancer subset.
Purpose of the Study:
- To investigate the molecular features of rCUP.
- To evaluate the clinical outcomes for patients with rCUP.
- To determine if rCUP benefits from treatments typically used for renal cell carcinoma (RCC).
Main Methods:
- Prospective identification and analysis of 25 rCUP cases.
- Molecular characterization of the rCUP cohort.
- Correlation of clinical data with molecular findings and treatment response.
Main Results:
- The study identified 25 prospectively confirmed cases of rCUP.
- Molecular profiling revealed similarities between rCUP and common subtypes of renal cell carcinoma (RCC).
- Patients with rCUP demonstrated positive responses to renal-tailored systemic treatments.
Conclusions:
- rCUP exhibits molecular characteristics akin to established renal cell carcinoma subtypes.
- Renal-tailored systemic therapy appears beneficial for patients diagnosed with rCUP.
- Integrating clinical and molecular data is essential for accurate rCUP diagnosis and effective management.
